AIDSWEEKLY Plus; Monday, May 10, 2004
Staff Medical Writers

In a study from the United States, the "associations between human immunodeficiency virus type 1 (HIV-1) intracellular DNA and immunological markers were analyzed longitudinally for children with sustained, undetectable RNA levels while receiving highly active antiretroviral therapy (HAART) for 12 years.

"When DNA levels reached a plateau at week 104 of therapy, in contrast to findings for adults, there was no correlation between the CD4+:CD8+ ratio and DNA levels (r=-0.02, p=0.95), and naïve CD4+CD45RA+ lymphocytes predominated," according to A. Saitoh and coauthors at the University of California-San Diego.

"These data suggest that the increased proportion of naïve lymphocytes found in children are less susceptible to HIV-1 infection than are the memory lymphocytes that dominate immune reconstitution in adults," the researchers concluded.

Saitoh and colleagues published their study in the Journal of Infectious Diseases (Longitudinal analysis of lymphocyte ratios and HIV-1 intracellular DNA levels in children. J Infect Dis. 2004 Apr 1;189(7):1216-20.

Additional information can be obtained by contacting S.A. Spector, University of California-San Diego, Department of Pediatrics, Division of Infection Diseases, Stein Clinical Research Bldg., Room 428, 9500 Gilman Dr., La Jolla, CA 92093 USA.

The publisher of the Journal of Infectious Diseases can be contacted at: University of Chicago Press, 1427 E. 60th St., Chicago, IL 60637-2954 USA.

The information in this article comes under the major subject areas of AIDS & HIV, Immunology, Pediatrics and Virology.

This article was prepared by AIDS Weekly editors from staff and other reports.

Reference

Saitoh A, Powell CA, Fenton T, et al., "Longitudinal analysis of lymphocyte ratios and HIV-1 intracellular DNA levels in children", J Infect Dis. 2004 Apr 1;189(7):1216-20

PubMED Related articles Search

040510
AW040504

Copyright © 2004 - Charles Henderson, Publisher. All rights Reserved. Permission to reproduce granted to AEGIS by Charles W. Henderson. Authorization to reproduce for personal use granted granted by C. W. Henderson, Publisher, provided that the fee of US$4.50 per copy, per page is paid directly to the Copyright Clearance Center, 27 Congress Street, Salem, Massachusetts 01970, USA. Published by Charles Henderson, Publisher. Editorial & Publishing Office: P.O. Box 5528, Atlanta, GA 30307-0528 / Telephone: (800) 633-4931; Subscription Office: P.O. Box 830409, Birmingham, AL 35283-0409 / FAX: (205) 995-1588 http://www.newsrx.net

AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, iMetrikus, Inc., John M. Lloyd Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2004. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright © 1980,2004. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.